Clinical observation of Tiaopi Shugan Yishen Decoction combined with chemotherapy in the treatment of postoperative recurrence of triple-negative breast cancer
|更新时间:2022-08-31
|
Clinical observation of Tiaopi Shugan Yishen Decoction combined with chemotherapy in the treatment of postoperative recurrence of triple-negative breast cancer
Shanghai Journal of Traditional Chinese MedicineVol. 52, Issue 9, Pages: 41-43(2018)
ZHANG Chencen, YOU Jianliang. Clinical observation of Tiaopi Shugan Yishen Decoction combined with chemotherapy in the treatment of postoperative recurrence of triple-negative breast cancer. [J]. Shanghai Journal of Traditional Chinese Medicine 52(9):41-43(2018)
DOI:
ZHANG Chencen, YOU Jianliang. Clinical observation of Tiaopi Shugan Yishen Decoction combined with chemotherapy in the treatment of postoperative recurrence of triple-negative breast cancer. [J]. Shanghai Journal of Traditional Chinese Medicine 52(9):41-43(2018) DOI: 10.16305/j.1007-1334.2018.09.012.
Clinical observation of Tiaopi Shugan Yishen Decoction combined with chemotherapy in the treatment of postoperative recurrence of triple-negative breast cancer
Objective:To investigate the clinical efficacy of Tiaopi Shugan Yishen Decoction combined with chemotherapy in the treatment of postoperative recurrence of triple-negative breast cancer. Methods50 patients with postoperative recurrence of triple-negative breast cancer were randomly divided into the treatment group and control group,25 cases in each group. The control group was treated with the XEC chemotherapy program (cyclophosphamide + epirubicin + capecitabine),and the treatment group was treated with Tiaopi Shugan Yishen Decoction based on the treatment for the control group,with a course of 6 months. The clinical efficacy on tumor and adverse reactions after chemotherapy were observed. The changes on life quality scores and levels of peripheral blood T lymphocyte subsets were compared. Results:①The total effective rates were 84.0% in the treatment group and 64.0% in the control group. The efficacy on tumor in the treatment group was obviously better than that in the control group (P,<,0.05). ②After treatment,the life quality scores of all items in the treatment group were obviously higher than those in the control group (P,<,0.05). ③After treatment,the levels of CD3,+,CD4,+, and CD4,+,/CD8,+, in the treatment group were obviously higher than those in the control group,while the CD8,+, level was obviously lower than that in the control group (P,<,0.05). ④The myelosuppression degree in the treatment group was obviously slighter than that in the control group (P,<,0.05),and the gastrointestinal toxic and side effects in the treatment group was also obviously slighter than that in the control group (P,<,0.05). Conclusion:Tiaopi Shugan Yishen Decoction combined with chemotherapy shows satisfactory efficacy in the treatment of triple-negative breast cancer,which can improve the life quality of patients,ameliorate the immune function (peripheral blood lymphocyte subsets) and reduce the myelosuppression and gastrointestinal toxic and side effects caused by chemotherapy alone.
关键词
三阴性乳腺癌术后复发调脾疏肝益肾法减毒增效T淋巴细胞亚群
Keywords
triple-negative breast cancerpostoperative recurrencetherapy of regulating spleensmoothing liver and benefiting kidneyreducing toxicity and enhancing efficacyT lymphocyte subsets
Retrospective study on factors related to recurrence and metastasis after radical resection of colorectal cancer
A retrospective cohort study on treatment of triple-negative breast cancer with Sanyin Decoction
Effect of Shuanglong Antifibrin Capsule on KL-6 and T lymphocyte subsets in patients with connective tissue disease associated with pulmonary fibrosis
Observation on efficacy of Kangliu Jiandu recipe combined with Shenqi Fuzheng injection in treating cancer-related fatigue in patients with intermediate-terminal non-small cell lung cancer
Effect of acupuncture combined with Western medicine on levels of T lymphocyte subsets, IL-4, IL-10 and VACM-1 in patients with moderate to severe intermittent allergic rhinitis
Related Author
No data
Related Institution
Cancer Institute, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Department of Oncology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, MOE Key Laboratory of Liver and Kidney Diseases
Department of Mammary Gland of Integrated Traditional Chinese and Western Medicine, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Department of Experimental Diagnostics, Pingan Hospital Affiliated to Hebei Medical University